Live
- 'Tarang Shakti' Exercise aimed at enhancing operational coordination among friendly countries: Rajnath Singh
- RG Kar protests: Mamata govt sends fresh invite for talks to protesting doctors
- Sensex, Nifty close at all-time high, led by metal and auto shares
- NGOs raise toxic air issue at Kelambakkam with TN Pollution Control Board
- JD-U leader slams Congress chief Kharge over criticism of NDA government
- Bangladesh's interim govt unveils plan to reform key sectors
- Telangana Govt. moves High Court Over Power Purchase Dispute with Chattisgarh
- Veteran CPI (M) leaders Sitaram Yechury passes away in Delhi
- RJD MLA backs Kharge's 'BJP leaders would be in jail' remarks
- IIT Mandi develops method to monitor ageing of bridges real-time using traffic data
Covid-19 variant KP.3.1.1 predominant in US as infections continue ticking up
The KP.3.1.1 Covid-19 variant, now the predominant SARS-CoV-2 variant circulating in the US, has been causing increasing infections in the country, the latest data from the Centers for Disease Control and Prevention (CDC) showed.
Los Angeles: The KP.3.1.1 Covid-19 variant, now the predominant SARS-CoV-2 variant circulating in the US, has been causing increasing infections in the country, the latest data from the Centers for Disease Control and Prevention (CDC) showed.
KP.3.1.1, of the Omicron family, is among many currently co-circulating JN.1-derived variants in the US, Xinhua news agency reported.
For the two-week period ending August 17, KP.3.1.1 is predicted to account for between 31 per cent and 43 per cent of Covid-19 clinical specimens, compared to between 20 per cent and 26 per cent for the two-week period ending August 3, according to the latest CDC data released.
The rise in prevalence of KP.3.1.1 comes as markers of Covid-19 activity, including test positivity, emergency department visits, and hospitalizations, remain elevated, particularly among adults ages 65 years and older and children younger than 2 years.
CDC recommends that the public get coronavirus vaccines to protect against serious illness from Covid-19 infection.
Updated Covid-19 vaccines that can provide protection during the 2024 to 2025 respiratory virus season will be available in the fall, according to the agency.
